7 September 2016 Two new faces have joined Birmingham-based venture capital specialists Midven’s growing team. Ben Reed, aged 21, and Joshua Rodger, aged 22, will support Midven’s investment management team in their roles as analysts. Both of the new recruits have run social enterprises whilst at university through their involvement with Enactus. Enactus is an […]
read moreAntibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17 November 2015 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody™ VH therapeutics, today announced the appointment of Dr. Kevin Johnson as non-executive Chairman of the Board of Directors. The appointment is effective immediately. Dr. Johnson brings […]
read more28 September 2015 Dr Mike Romanos as consultant venture partner. Mike will be supporting Rainbow in its investment decisions and providing general advice and strategic guidance to portfolio companies to help maximise their potential. Mike brings an exceptional breadth and depth of experience in drug development, technology and commercialisation gained over many years in the […]
read more